logo
Insurance firm told to refund Rs 15 lakh to 83-year-old Udupi man misled on policy, additional Rs 20,000 for mental harassment

Insurance firm told to refund Rs 15 lakh to 83-year-old Udupi man misled on policy, additional Rs 20,000 for mental harassment

Time of India4 days ago

Representative Image
UDUPI: The Udupi District Consumer Disputes Redressal Commission has ordered an insurance company to refund Rs 15 lakh to a senior citizen and pay an additional Rs 20,000 as compensation for mental harassment and legal expenses.
Dr Ravindranath Shanbhag, President of the Human Rights Protection Foundation (HRPF), Udupi, told reporters on Thursday that Annappa Poojary, 83, a resident of Belur in Kundapur taluk, used to run a business in Hubballi for his livelihood.
After suffering a paralytic stroke 15 years ago, he returned to his hometown and began living with his wife. Although he had children, they were not financially capable of supporting their parents, forcing Poojary to sell his property in Kundapur.
After the sale, he decided to deposit the proceeds of Rs30 lakh in fixed deposits, intending to live off the interest income. When Poojary consulted an insurance agent, he was advised to invest the amount in the "Pradhan Mantri Vaya Vandana Yojana" (PMVVY), a subsidised scheme for senior citizens.
T
he agent assured him that the scheme offered higher returns and allowed premature withdrawal in case of emergencies.
Trusting the agent, Poojary invested his entire Rs30 lakh under the condition that he would be able to withdraw the amount if needed. Soon after, he received two policies of Rs15 lakh each. Being illiterate, Poojary and his wife could not read the policy documents, which were in English, and relied solely on the agent's assurances.
Months later, when Poojary checked his passbook, he noticed that the first deposit earned Rs9,250 in interest, while the second earned only Rs 6,519.
When questioned, the agent failed to provide a proper explanation. Already battling paralysis, Poojary was also diagnosed with Parkinson's disease.
He frequently had to travel 45 km to Manipal for treatment. The combined interest of around Rs 15,000 from both deposits was insufficient to meet his medical and living expenses.
He decided to withdraw the lower-interest policy and repeatedly contacted the insurance company's office and the agent.
Receiving no response, he formally requested the surrender of one of the policies on January 11, 2023.
He was shocked to discover that the policy, purchased on September 6, had a surrender value of only Rs10,73,412 after 16 months, meaning he would lose Rs4,26,588. He claimed he was never informed about the massive penalty for premature withdrawal.
He then sought assistance from the HRPF, Udupi. The foundation guided him to file a complaint with the Udupi District Consumer Commission.
Shanbhag said the company argued that the first policy was under the PMVVY, while the second was under a different plan. They claimed the policyholder had a 15-day 'free-look' period to cancel the policy but failed to do so. However, the company could not produce any evidence that these terms were ever explained to the illiterate Poojary couple, he added.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Zydus Lifesciences gets USFDA nod for Rifaximin tablets
Zydus Lifesciences gets USFDA nod for Rifaximin tablets

Business Standard

timean hour ago

  • Business Standard

Zydus Lifesciences gets USFDA nod for Rifaximin tablets

Zydus Lifesciences announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for Rifaximin tablets, 550 mg, under the reference listed drug (RLD) Xifaxan tablets, 550 mg. Rifaximin tablets are indicated for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults. The tablets will be produced at the Group's manufacturing facility at SEZ II, Ahmedabad. According to IQVIA MAT 2025, Rifaximin tablets had annual sales of USD $2,672.9 million in the United States. The group now has 427 approvals and has filed 492 Abbreviated New Drug Applications (ANDAs) since the commencement of the filing process in FY 2003-04. The companys consolidated net profit shed 0.96% to Rs 1,170.9 crore on 17.21% rise in revenue from operations to Rs 6290.2 crore in Q4 FY25 over Q4 FY24. Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies. Shares of Zydus Lifesciences shed 0.53% to Rs 924.95 on the BSE.

Zydus gets USFDA nod for generic IBS-D treatment drug
Zydus gets USFDA nod for generic IBS-D treatment drug

Time of India

timean hour ago

  • Time of India

Zydus gets USFDA nod for generic IBS-D treatment drug

Zydus Lifesciences on Monday said it has received approval from the US health regulator to market a drug for the treatment of irritable bowel syndrome with diarrhoea in adults. The company has received tentative approval from the US Food and Drug Administration (USFDA) for Rifaximin Tablets (550 mg), the drug manufacturing firm said in a regulatory filing. Rifaximin tablets are indicated for the treatment of irritable bowel syndrome with diarrhoea ( IBS-D ) in adults. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Access all TV channels anywhere, anytime Techno Mag Learn More Undo As per the IQVIA MAT March sales data, Rifaximin tablets had an annual sales of USD 2,672.9 million in the US. Shares of Zydus Lifesciences were trading at Rs 926.05 apiece, 0.41 per cent down from previous close, on BSE.

AstraZeneca Pharma soars after Q4 PAT jumps 48% YoY
AstraZeneca Pharma soars after Q4 PAT jumps 48% YoY

Business Standard

time3 hours ago

  • Business Standard

AstraZeneca Pharma soars after Q4 PAT jumps 48% YoY

AstraZeneca Pharma surged 10.03% to Rs 8764.05 after the company's standalone net profit rose 47.54% to Rs 58.25 crore, while revenue from operations rose 25.39% to Rs 480.48 crore in Q4 March 2025 over Q4 March 2024. Profit before tax (PBT) stood at Rs 78.47 crore in Q4 FY25, up 44.35% year-on-year, and up 86.74% quarter-on-quarter. Total expenses rose 22.22% to Rs 412.48 crore in Q4FY25 over Q4FY24. During the quarter, cost of materials consumed stood at Rs 94.25 crore (up 180.34% YoY) while employee benefits expense was at Rs 66.07 crore (up 13.95% YoY). The company's net profit surged 88.82% while net sales rose 9.13% in Q4 March 2025 over Q3 December 2024. For the full year FY25, revenue from operations rose 32.48% to Rs 1,716.29 crore, while net profit fell 28.34% to Rs 115.74 crore. PBT fell 28.78% to Rs 156.36 crore compared to FY24. The company's standalone net cash from operating activities stood at Rs 65.36 crore in FY25, as against Rs 27.87 crore in FY24. Dr. Sanjeev Panchal, country president & managing director of the company, said, "Our company delivered strong growth in Financial Year 2024-25 by launching innovative medicines in India, giving us momentum into 2025 and beyond. We are pleased to share that our company has, for the first time, crossed the INR 1,700 crore mark ($200 million)." The board recommended dividend of Rs 32 per equity share for FY25. AstraZeneca is a global biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines in four areas: Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Rare Diseases. It operates in over 100 countries.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store